News from boehringer ingelheim A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

13 Mar, 2018, 13:00 GMT Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Boehringer Ingelheim and Vanderbilt University today announced the expansion of their successful existing collaboration to develop novel anti-cancer...


24 Nov, 2014, 13:00 GMT Nintedanib* Receives Positive CHMP Opinion in European Union for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Recommendation supported by data from two identical Phase III trials involving more than 1,000 patients[1] Data showed that nintedanib[*]slowed...


15 Jul, 2014, 08:00 BST Pradaxa® (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Prevention of Recurrence

Pradaxa® is as effective as warfarin in the treatment and secondary prevention of DVT and PE with significantly fewer major, or clinically relevant...


02 Jul, 2014, 09:00 BST Boehringer Ingelheim Submits Marketing Authorisation Applications in Europe for tiotropium + olodaterol Respimat® Fixed-dose Combination in COPD

Applications are supported by data from the TOviTO™ Phase III clinical trial programme involving more than 8,000 patients[1] First Phase III data...


05 Jun, 2014, 07:00 BST European Medicines Agency (EMA) Accepts Accelerated Marketing Authorisation Application for nintedanib* in IPF

Acceptance of accelerated marketing authorisation application marks the beginning of the regulatory review process for nintedanib* in IPF in the EU...


08 Sep, 2013, 23:01 BST Landmark TIOSPIR™ Trial Further Reinforces Safety and Efficacy Profile of Spiriva® Respimat® in the Treatment of COPD

One of largest chronic obstructive pulmonary disease (COPD) trials conducted to-date confirms comparable safety and efficacy profile of Spiriva®...


21 May, 2013, 14:07 BST Phase III Results: Once-daily Tiotropium* Effective in Symptomatic Asthma Patients Irrespective of Their Age, Allergic Status, Smoking Status and Bronchodilator Response

For UK medical, health correspondents and business media Tiotropium delivered by the Respimat® Soft Mist™ Inhaler (SMI) increases time to first...


08 Nov, 2012, 12:10 GMT RELY-ABLE® Study Demonstrates Benefits of Pradaxa® (Dabigatran Etexilate) Are Maintained for over Four Years

Pradaxa® (dabigatran etexilate) is the first and only novel oral anticoagulant supported by long-term clinical data of 4.3 years' duration Benefits...


24 Mar, 2011, 23:34 GMT Boehringer Ingelheim Finalizes Acquisition of Amgen's Fremont Facility in the USA

- Boehringer Ingelheim Strengthens Global Biopharma Presence. Today Boehringer Ingelheim formally acquired Amgen's biopharmaceutical development and...